Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Surgical Oncology|October 12, 2013
Management and clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2006 and 2008L Moureau-Zabotto, M Resbeut, J Gal, et al.
Neuroscience Letters|October 4, 1996
1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brainE Garcion, X D Thanh, F Bled, et al.
FEBS Letters|February 20, 2002
Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophagesF G Gbaguidi, G Chinetti, D Milosavljevic, et al.
Bulletin Du Cancer|January 1, 1997
[A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer]J M Ferrero, M Namer, J F Dufour, et al.
Journal of Cardiovascular Pharmacology|October 22, 1998
A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cellsE Walters-Laporte, C Furman, S Fouquet, et al.
Breast Cancer Research and Treatment|April 29, 2010
Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complicationsDidier Cowen, E Gross, P Rouannet, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 3, 2010
[Evaluation of immediate breast reconstruction and radiotherapy: factors associated with complications]E Gross, J-M Hannoun-Levi, P Rouanet, et al.
Bulletin Du Cancer|March 1, 1993
[Demonstration and characterization of EGF receptors in cancer of the uterine cervix]J L Lagrange, M Francoual, J L Formento, et al.
British Journal of Cancer|January 19, 2000
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patientsJ M Ferrero, M C Etienne, J L Formento, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)C Delbaldo, D Serin, M Mousseau, et al.
Pageof 5